Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Rating of “Buy” by Analysts

Palvella Therapeutics, Inc. (NASDAQ:PVLA) has been assigned an average recommendation of “Buy” from the fourteen analysts that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, eleven have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $121.7692.

Several research firms have recently weighed in on PVLA. Chardan Capital restated a “buy” rating and issued a $110.00 price target on shares of Palvella Therapeutics in a research note on Thursday, November 13th. Raymond James Financial raised Palvella Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price objective for the company from $92.00 to $143.00 in a research report on Wednesday, November 19th. Stifel Nicolaus boosted their target price on Palvella Therapeutics from $87.00 to $145.00 and gave the stock a “buy” rating in a research report on Monday, November 24th. HC Wainwright upped their target price on shares of Palvella Therapeutics from $95.00 to $190.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Finally, Cantor Fitzgerald raised their price target on shares of Palvella Therapeutics from $120.00 to $200.00 and gave the company an “overweight” rating in a report on Thursday, November 6th.

Insider Transactions at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $86.23, for a total value of $370,961.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Palvella Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of PVLA. Archer Investment Corp purchased a new position in shares of Palvella Therapeutics in the 3rd quarter worth $28,000. Russell Investments Group Ltd. bought a new position in Palvella Therapeutics in the third quarter valued at about $36,000. Police & Firemen s Retirement System of New Jersey purchased a new position in Palvella Therapeutics in the second quarter worth about $37,000. JPMorgan Chase & Co. boosted its position in Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after purchasing an additional 3,242 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Palvella Therapeutics during the 2nd quarter valued at about $85,000. 40.11% of the stock is owned by institutional investors.

Palvella Therapeutics Stock Performance

Shares of NASDAQ PVLA opened at $93.80 on Friday. The firm’s 50 day moving average price is $79.06 and its 200-day moving average price is $51.57. Palvella Therapeutics has a 52-week low of $11.17 and a 52-week high of $106.71. The company has a market cap of $1.11 billion, a PE ratio of -35.67 and a beta of -0.20.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings data on Monday, November 10th. The company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18). On average, analysts forecast that Palvella Therapeutics will post -3.69 earnings per share for the current fiscal year.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.